Market Overview

BMO Capital Upgrades Halozyme Therapeutics, Inc. to Outperform, Raises to $12.00

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for HALO

DateFirmActionFromTo
Sep 2014JefferiesMaintainsUnderperform
Jul 2014JP MorganInitiates Coverage onOutperform
Jun 2014UBSUpgradesNeutralBuy

View More Analyst Ratings for HALO
View the Latest Analyst Ratings

Posted-In: News Upgrades Analyst Ratings

 

Related Articles (HALO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters